Pages that link to "Q31142368"
Jump to navigation
Jump to search
The following pages link to Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. (Q31142368):
Displaying 50 items.
- New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists (Q26748617) (← links)
- Gut Microbiota: The Brain Peacekeeper (Q26751052) (← links)
- Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications (Q26775927) (← links)
- Gut microbiota and allogeneic transplantation (Q26795634) (← links)
- Profile of rifaximin and its potential in the treatment of irritable bowel syndrome (Q26829363) (← links)
- Application of metagenomics in the human gut microbiome (Q26851464) (← links)
- Regulation of the serotonin transporter in the pathogenesis of irritable bowel syndrome (Q28072085) (← links)
- Metagenomic Assembly: Overview, Challenges and Applications (Q28072693) (← links)
- Irritable bowel syndrome: a microbiome-gut-brain axis disorder? (Q34366837) (← links)
- Activation of intestinal human pregnane X receptor protects against azoxymethane/dextran sulfate sodium-induced colon cancer (Q34573895) (← links)
- Does stress induce bowel dysfunction? (Q34598208) (← links)
- Stress-induced visceral pain: toward animal models of irritable-bowel syndrome and associated comorbidities (Q35087100) (← links)
- Specific changes of gut commensal microbiota and TLRs during indomethacin-induced acute intestinal inflammation in rats. (Q35102353) (← links)
- Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets (Q35130485) (← links)
- Antibiotic-induced dysbiosis alters host-bacterial interactions and leads to colonic sensory and motor changes in mice. (Q35532177) (← links)
- The structures of the colonic mucosa-associated and luminal microbial communities are distinct and differentially affected by a prolonged murine stressor (Q35533302) (← links)
- Growth promotion and gut microbiota: insights from antibiotic use. (Q35550444) (← links)
- Does low-dose rifaximin ameliorate endotoxemia in patients with liver cirrhosis: a prospective study (Q35810550) (← links)
- Background Intestinal 18F-FDG Uptake Is Related to Serum Lipid Profile and Obesity in Breast Cancer Patients (Q35828985) (← links)
- The joint power of sex and stress to modulate brain-gut-microbiota axis and intestinal barrier homeostasis: implications for irritable bowel syndrome. (Q35838055) (← links)
- Review article: the antimicrobial effects of rifaximin on the gut microbiota (Q35855732) (← links)
- Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea (Q35855740) (← links)
- Impact of 4-epi-oxytetracycline on the gut microbiota and blood metabolomics of Wistar rats (Q35956933) (← links)
- Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation. (Q36009729) (← links)
- Background Colonic 18F-Fluoro-2-Deoxy-D-Glucose Uptake on Positron Emission Tomography Is Associated with the Presence of Colorectal Adenoma (Q36100290) (← links)
- Irritable Bowel Syndrome: Peripheral Mechanisms and Therapeutic Implications (Q36207200) (← links)
- Isomalto-oligosaccharides ameliorate visceral hyperalgesia with repair damage of ileal epithelial ultrastructure in rats. (Q36355131) (← links)
- Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome. (Q37303691) (← links)
- Xenobiotic Receptor-Mediated Regulation of Intestinal Barrier Function and Innate Immunity (Q37486151) (← links)
- The effect of gut microbiome on tolerance to morphine mediated antinociception in mice (Q37648767) (← links)
- Low-dose penicillin exposure in early life decreases Th17 and the susceptibility to DSS colitis in mice through gut microbiota modification (Q37686653) (← links)
- Rifaximin: beyond the traditional antibiotic activity (Q38237218) (← links)
- Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome. (Q38340085) (← links)
- Animal models of gastrointestinal and liver diseases. Animal models of visceral pain: pathophysiology, translational relevance, and challenges (Q38376282) (← links)
- Gut microbiota and physiologic bowel 18F-FDG uptake (Q38598373) (← links)
- Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome (Q38692607) (← links)
- Rifaximin has minor effects on bacterial composition, inflammation and bacterial translocation in cirrhosis; A randomized trial (Q38696806) (← links)
- Rifaximin in non-alcoholic steatohepatitis: An open-label pilot study. (Q38829371) (← links)
- Critical Evaluation of Animal Models of Gastrointestinal Disorders (Q38973036) (← links)
- Structural and functional alterations in the colonic microbiome of the rat in a model of stress induced irritable bowel syndrome (Q39036457) (← links)
- Randomised clinical trial: rifaximin versus placebo for the treatment of functional dyspepsia. (Q39160800) (← links)
- Pathophysiology of irritable bowel syndrome (Q39238569) (← links)
- Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation (Q39455595) (← links)
- Subacute stress and chronic stress interact to decrease intestinal barrier function in rats. (Q39944908) (← links)
- Piezo2: A Candidate Biomarker for Visceral Hypersensitivity in Irritable Bowel Syndrome? (Q40387665) (← links)
- Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition (Q41246828) (← links)
- Synergic Interaction of Rifaximin and Mutaflor (Escherichia coli Nissle 1917) in the Treatment of Acetic Acid-Induced Colitis in Rats (Q42002312) (← links)
- Moody microbes or fecal phrenology: what do we know about the microbiota-gut-brain axis? (Q42874439) (← links)
- Carrion's Disease: the Sound of Silence. (Q46251748) (← links)
- Psychological stress exacerbates NSAID-induced small bowel injury by inducing changes in intestinal microbiota and permeability via glucocorticoid receptor signaling (Q46564025) (← links)